Key facts
- This page summarizes Justin J. File's Form 5 filing for Evofem Biosciences, Inc. (EVFM).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 May 2023, 16:05.
Justin J. File - 31 Dec 2022 Form 5 Insider Report for Evofem Biosciences, Inc. (EVFM)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- EVFM
- Reported as of
- 31 Dec 2022
- Net transaction value
- $0
- SEC form
- 5
- Accepted by SEC
- 08 May 2023, 16:05:19 UTC
- Prior SEC filing
- 23 Feb 2022
- Next SEC filing
- 01 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Justin J. File
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Justin J. File filed Form 5 for Evofem Biosciences, Inc. (EVFM) on 08 May 2023.
Change
- Previous filing in this sequence was filed on 23 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 5 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EVFM
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $0
- Shares
- -30,000
- Change %
- -55%
- Price
- $0.000000
- Shares after
- 24,065
- Date
- 31 Dec 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The disposition is due to forfeiture under the vesting provisions of restricted stock awards granted on 2/18/2022.
SEC remarks
Mr. File resigned as a chief financial officer effective April 3, 2023.